In postmenopausal women, bone density trajectories differed between calcitonin plus calcium and calcium alone from the sixth month onward (P < 0.001).
In plain wordsIn postmenopausal women, calcitonin plus calcium preserved bone density better than calcium alone from the sixth month onward.
- Peptide
- Calcitonin-salmon
- Outcome
- IncreaseLumbar bone density trajectory
- Study
n = 87
- Comparator
- Calcium alone
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 50 IU daily, 5 days per week · intranasal · 5 yearsAs given in this study (human).
Measurements
- P value for difference in BMD evolution
- < 0.001
- calcium plus calcitonin versus calcium alone
Source sentences
The evolution of BMD in the two groups was highly significantly different (P < 0.001) since the sixth month of the study and remained so until the end of the study.(ABSTRACT TRUNCATED AT 250 WORDS)
4 context sentences(design, population, supporting numbers)
The women receiving calcium alone presented a significant decrease in 1-BMD after 6 months [-1.6 (0.5)%] [mean(SEM)] (P < 0.01) and this decrease remained significant after 36 months [-6.1(0.8)%] (P < 0.01) and until the end of the trial [-6.6(1.0)% at t60] (P < 0.01).
In women receiving calcium and calcitonin, 1-BMD significantly increased after 36 months [+2(0.7%] (P < 0.01) and 42 months [+2.5(0.7)%] (P < 0.01 and was unchanged at the other times of investigation [+1.1 (1.1)% at t60] (NS).
The aim of this paper was to evaluate the long-term (5 years) efficacy of nasal salmon calcitonin in prevention of trabecular postmenopausal bone loss, which was a follow-up of a previously published study (3 years); a randomized, controlled group comparison.
The 100 women were allocated to an additional 2 year period (total of 5 years) of treatment with either 500 mg d-1, 5 days week-1 of calcium or the same amount of calcium plus 50 IU d-1, 5 days per week of nasal salmon calcitonin, 87 (87%) women complied with the protocol throughout.